NCT07552922Recruiting
Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1
Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Qualitative Stage
Source: ClinicalTrials.gov · Last updated 27 Apr 2026
Brief summary (registry, in English)
This study aims to explore the perceptions of men with prostate cancer (PCa) and high-risk biochemical recurrence (BCR) regarding the risk of breast-related side effects, including gynaecomastia, from treatment.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 21 Sept 2025
- Start date
- 1 Dec 2025
- Primary completion date
- 30 May 2026
- Lead sponsor
- St Vincent's Hospital, Sydney
- Diseases
- Prostate cancer
- NCT number
- NCT07552922
What you commit to
- Study type: Interventional
- Planned participants: 24
- From 1 Dec 2025 to the primary completion date, 30 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Men receiving psychiatric care as a consequence of their prostate cancer diagnosis or treatment thereof.
Who the study is looking for
- Men with high-risk BCR PCa but no ADT+/-ARPI experience.
- Men with ADT+/-ARPI experience who have experienced breast-related side effects from this treatment.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kinghorn Cancer Centre Coordinator of this site? Confirm its status | Sydney | Australia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.